Eli Lilly and Company (NEO:LLY)

Market Cap	847.90B
Revenue (ttm)	72.64B
Net Income (ttm)	18.82B
Shares Out	n/a
EPS (ttm)	20.86
PE Ratio	45.05
Forward PE	24.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,720
Average Volume	108,333
Open	25.47
Previous Close	25.11
Day's Range	25.13 - 25.61
52-Week Range	22.85 - 36.42
Beta	0.44
RSI	42.01
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD